Home/Pipeline/Neural Stem Cell Therapy for Parkinson's

Neural Stem Cell Therapy for Parkinson's

Parkinson's Disease

Pre-clinicalActive

Key Facts

Indication

Parkinson's Disease

Phase

Pre-clinical

Status

Active

Company

Neoneuron

About Neoneuron

Founded in 2018 and based in Boston, NeoNeuron is a private, pre-clinical stage biotech developing regenerative therapies for neurological disorders. The company's core expertise lies in purifying homogeneous neural stem cell lines and directing their differentiation to replace lost neurons, primarily targeting Parkinson's disease and ischemic stroke. Operating with a patient-centered approach, NeoNeuron advances its programs through internal R&D, strategic partnerships, and contract research services in validated animal models. The company is currently pre-revenue, focusing on translating its scientific platform into therapeutic candidates.

View full company profile

Therapeutic Areas

Parkinson's Disease Ischemic Stroke Neurodegenerative Diseases Brain Injury

Other Parkinson's Disease Drugs

Drug	Company	Phase	Status
NPT200-11	Neuropore Therapies	Phase 1	Partnered (UCB Pharma), status unclear
NUZ-001	Neurizon Therapeutics	Preclinical	Active
VXX-301	Vaxxinity	Preclinical	Pipeline
BAN2802	BioArctic	Phase 1	Active
CNM-Au8	Clene	Phase 2	Active
hpSC-Derived Neural/Dopaminergic Cells	International Stem Cell	Preclinical/Early Clinical	Inferred Active
SLS-004	Seelos Therapeutics	Preclinical	Research
SLS-007	Seelos Therapeutics	Preclinical	Research
Parkinson's Disease Portfolio (Platform-derived)	WD Pharmaceutical	Not Disclosed (Likely Preclinical/Early Clinical)	Active
UX-DA001	UniXell	Phase 1	Active, with trials ongoing in China and FDA IND cleared in U.S. (as of April 2025)
Parkinson's Disease Research	ProgenaBiome	Research	Active
A9 Dopaminergic Neuron Therapy	Trailhead Biosystems	Pre-clinical	Active